ISDA

Entry Detail

PDB ID:

3M2W

Keywords:

TRANSFERASE

Title:

Crystal structure of MAPKAK kinase 2 (MK2) complexed with a spiroazetidine-tetracyclic ATP site inhibitor

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2010-03-08

Release Date:

2010-07-28

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.41 Å

R-Value Free:

0.22

R-Value Work:

0.18

R-Value Observed:

0.18

Space Group:

P 63 2 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:MAP kinase-activated protein kinase 2
Mutations:DELTA216-236, P237G
Chain IDs:A
Chain Length:299
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P49137 Pfam ID:PF00069 EC:2.7.11.1

Ligand Molecules

L8I

Primary Citation

In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II.

Revesz, L, Schlapbach, A, Aichholz, R, Dawson, J, Feifel, R, Hawtin, S, Littlewood-Evans, A, Koch, G, Kroemer, M, Mobitz, H, Scheufler, C, Velcicky, J, Huppertz, C.Show

Bioorg.Med.Chem.Lett. 20 4719 4723 (2010)

PMID: 20591669 DOI: 10.1016/j.bmcl.2010.04.023

Abstact

Spirocyclopropane- and spiroazetidine-substituted tetracycles 13D-E and 16A are described as orally active MK2 inhibitors. The spiroazetidine derivatives are potent MK2 inhibitors with IC(50)<3 nM and inhibit the release of TNFalpha (IC(50)<0.3 microM) from hPBMCs and hsp27 phosphorylation in anisomycin stimulated THP-1 cells. The spirocyclopropane analogues are less potent against MK2 (IC(50)=0.05-0.23 microM), less potent in cells (IC(50)<1.1 microM), but show good oral absorption. Compound 13E (100mg/kg po; bid) showed oral activity in rAIA and mCIA, with significant reduction of swelling and histological score.

Legend

Protein

Chemical

Disease

Primary Citation of related structures